SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SpectraScience, Inc. , a San Diego based medical device company, today announced that it will hold its annual shareholders meeting at 9:00 AM on May 5, 2008 at the University Club in St. Paul, MN.
Shareholders who held SpectraScience stock as of the close of business on March 31, 2008 and those who hold a valid proxy for the meeting are entitled to attend in person.
Jim Hitchin, CEO of SpectraScience, Inc. said, “I look forward to meeting with our shareholders to talk about our recent historical results and our plans for the future.”
Additional information, including details of the business to be conducted at the annual meeting, is included in the Company’s Notice of Annual Meeting of Shareholders and Proxy Statement, which has been filed with the Securities and Exchange Commission and mailed to all shareholders of record.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT(R) Optical Biopsy System uses light to optically scan tissue and provides the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA(R) cervical imaging technology has received FDA approval as an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.
CONTACT: Jim Hitchin, Chief Executive Officer of SpectraScience, Inc.,
+1-858-847-0200, ext. 201; or investors, Todd Pitcher of Hayden
Communications, +1-858-518-1387, for SpectraScience, Inc.
Web site: http://www.spectrascience.com/
